{"id":"abt-199-and-ibrutinib-combination","safety":{"commonSideEffects":[{"rate":"44%","effect":"Neutropenia"},{"rate":"35%","effect":"Thrombocytopenia"},{"rate":"31%","effect":"Anemia"},{"rate":"24%","effect":"Diarrhea"},{"rate":"22%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ABT-199 is a BCL-2 inhibitor, and Ibrutinib is a BTK inhibitor. This combination targets both B-cell receptor signaling and apoptosis pathways.","oneSentence":"BCL-2 inhibitor and BTK inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:52:01.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04840602","phase":"PHASE2","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-01-05","conditions":"Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia","enrollment":92},{"nctId":"NCT03701282","phase":"PHASE3","title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":720},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":120},{"nctId":"NCT03462719","phase":"PHASE3","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-17","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":211},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT04739813","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-09","conditions":"Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":55},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT02427451","phase":"PHASE1, PHASE2","title":"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kerry Rogers","startDate":"2015-08-03","conditions":"Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia","enrollment":87},{"nctId":"NCT03708003","phase":"PHASE2","title":"Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2019-03-11","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia","enrollment":30},{"nctId":"NCT03342144","phase":"","title":"Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting","status":"RECRUITING","sponsor":"AbbVie","startDate":"2017-12-04","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":500},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT06958705","phase":"PHASE2","title":"Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-01","conditions":"Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)","enrollment":79},{"nctId":"NCT05105841","phase":"PHASE2","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-11-08","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":20},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT04273139","phase":"PHASE2","title":"Ibrutinib + Venetoclax in Untreated WM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-09","conditions":"Waldenstrom Macroglobulinemia, MYD88 Gene Mutation","enrollment":45},{"nctId":"NCT02558816","phase":"PHASE1, PHASE2","title":"A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2015-10-14","conditions":"Mantle Cell Lymphoma","enrollment":48},{"nctId":"NCT03112174","phase":"PHASE3","title":"Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-06-19","conditions":"Mantle-Cell Lymphoma","enrollment":366},{"nctId":"NCT04477486","phase":"PHASE2","title":"Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-23","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":13},{"nctId":"NCT03295240","phase":"EARLY_PHASE1","title":"The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-20","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":10},{"nctId":"NCT04450173","phase":"PHASE2","title":"Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2021-02-24","conditions":"Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma","enrollment":40},{"nctId":"NCT02910583","phase":"PHASE2","title":"Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2016-09-28","conditions":"Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":323},{"nctId":"NCT04939363","phase":"PHASE2","title":"A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;","status":"COMPLETED","sponsor":"Bnai Zion Medical Center","startDate":"2021-08-08","conditions":"Richter's Syndrome","enrollment":12},{"nctId":"NCT05864742","phase":"PHASE2","title":"Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2023-09-07","conditions":"Mantle Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT04758975","phase":"PHASE2","title":"Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"Paolo Ghia","startDate":"2022-09-19","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":55},{"nctId":"NCT02419560","phase":"PHASE1","title":"Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL","status":"COMPLETED","sponsor":"Craig Portell, MD","startDate":"2015-04","conditions":"Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell","enrollment":37},{"nctId":"NCT02406742","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-07-27","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":47},{"nctId":"NCT04639362","phase":"PHASE2","title":"CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2020-12-29","conditions":"CLL","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GDC-0199","venetoclax","PCI-32765"],"phase":"phase_1","status":"active","brandName":"ABT-199 and Ibrutinib Combination","genericName":"ABT-199 and Ibrutinib Combination","companyName":"Craig Portell, MD","companyId":"craig-portell-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCL-2 inhibitor and BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}